We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Autosomal Dominant Disorder Confirmed by Biomarker Assay

By LabMedica International staff writers
Posted on 06 Feb 2012
The erythrocyte glucose-uptake assay has been used to confirm the diagnosis of glucose transporter type 1 deficiency syndrome (Glut1-DS). More...


The disease is diagnosed with cerebrospinal fluid (CSF) glucose values of less than 2.2 mmol/L, or lowered CSF/plasma glucose ratio of less than 0.4, and the erythrocyte 3-O-methyl-d-glucose uptake assay (3-OMG).

Scientists at Columbia University (New York, NY, USA) studied 109 suspected cases of Glut-1 DS, all who had a consistent clinical picture and a low CSF glucose concentration (hypoglycorrhachia). To confirm the diagnosis of Glut1 DS, blood samples from both patients and parents were analyzed using the erythrocyte 3-OMG uptake assay. The erythrocytes are radioactively labeled and measured on a scintillation counter.

Copy number analysis was performed via single nucleotide polymorphism (SNP) oligonucleotide microarray analysis (SOMA) using the Affymetrix Genome Wide Human SNP Array 6.0 (Santa Clara, CA, USA), which includes over 906,600 SNPs and more than 946,000 probes for the detection of copy number variation. A multiplex ligation-dependent probe amplification (MLPA) kit (MRC-Holland; Amsterdam, Netherlands) was used to screen eight patients with decreased 3-OMG uptake without identified sequence based mutations or deletions using SOMA. .

The uptake assay was decreased in 74 cases (group 1) and normal in 35 cases (group 2). The disease-causing mutations were identified in 70 group 1 patients (95%) and only one in group 2 patients (3%). The cut-off for an abnormally low uptake value was increased from 60% to 74% with a corresponding sensitivity of 99% and specificity of 100%. The correlation between the uptake values for the time-curve and the kinetic concentration curve were strongly positive. There was a significant correlation between the mean erythrocyte 3-OMG uptake and clinical severity.

The authors concluded that the erythrocyte glucose-uptake assay, when abnormal, essentially confirms the clinical suspicion of Glut1 DS. Furthermore, the degree of uptake abnormality correlates with glucose transport functional activity and has implications regarding clinical severity and prognosis. Glut1 deficiency syndrome is characterized classically by infantile onset seizures, delayed neurological development, disorders of movement, and acquired microcephaly. The study was published in December 2011, in the Annals of Neurology.

Related Links:

Columbia University
Affymetrix
MRC-Holland



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Host Response Immunoassay Test
MeMed BV
New
Pan-Cancer Panel
TruSight Oncology 500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.